Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
News|Videos|December 7, 2015
Pharmacist Role in ACS Management with Platelet Aggregation Inhibitors
Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses the role of the pharmacist in ACS management with platelet aggregation inhibitors.
Advertisement
Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses the role of the pharmacist in ACS management with platelet aggregation inhibitors.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5